Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Checkpoint Therapeutics Announces Pricing of Public Offering of Common Stock

Nov 20, 2019

Checkpoint Therapeutics Announces Proposed Public Offering of Common Stock

Nov 19, 2019

Fortress Biotech Ranked in Top 10 of Deloitte’s 2019 Technology Fast 500™

Nov 14, 2019

Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

Nov 12, 2019

Fortress Biotech Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

Nov 12, 2019

Checkpoint Therapeutics Announces Presentation of Anti-PD-L1 Cosibelimab Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 08, 2019

Checkpoint Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

Nov 07, 2019

Mustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of Hematology Annual Meeting

Nov 06, 2019

Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

Nov 04, 2019

Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development

Oct 28, 2019
RSS
  • Prev
    • 1...
    • 43
    • 44
    • 45
    • 46
    • 47
    • 48
    • 49
    • 50
    • 51
    • 52
    • ...71
    Next

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2025 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap